Evolocumab treatment in paediatric patients with homozygous familial hypercholesterolaemia: the Trial Assessing long-term Use of PCSK9 inhibition in Subjects with Genetic LDL disorders (TAUSSIG)

Back

ESC Premium Access

Evolocumab treatment in paediatric patients with homozygous familial hypercholesterolaemia: the Trial Assessing long-term Use of PCSK9 inhibition in Subjects with Genetic LDL disorders (TAUSSIG)

Session: Lipid lowering therapy in primary cardiovascular prevention

Topic: Lipids (Epidemiology and Prevention)

Speaker: Professor F. Raal (Johannesburg, ZA)

Event: ESC Congress 2017

Congress Presentation

About the speaker

Professor Frederick Raal

University of the Witwatersrand, Johannesburg (South Africa)

1 presentation

0 follower

8 more presentations in this session

Risk of incident atherosclerotic cardiovascular disease events by atherogenic lipid levels in a real-world population of 62,428 on-statin individuals with diabetes

Speaker: Assistant Professor J. Rana (Oakland, US)

Assessing gaps in cholesterol treatment guidelines for primary prevention of cardiovascular disease using clinical trial evidence: results from the prospective population-based Rotterdam Study

Speaker: Doctor M. Leening (Rotterdam, NL)

Effects of morning versus evening statin therapy on lipid profile: A systematic review and meta-analysis

Speaker: Doctor P. Penson (Liverpool, GB)

Familial hypercholesterolemia: development of a next generation sequencing approach to the disease

Speaker: Associate Professor R. Marcucci (Florence, IT)

Comprehensive genotyping and phenotyping in patients with severe hypercholesterolemia

Speaker: Doctor H. Tada (Kanazawa, JP)

Access the full session

Lipid lowering therapy in primary cardiovascular prevention

Speakers: Professor F. Raal, Assistant Professor J. Rana, Doctor M. Leening, Doctor P. Penson, Associate Professor R. Marcucci...

Access

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

Evolocumab treatment in paediatric patients with homozygous familial hypercholesterolaemia: the Trial Assessing long-term Use of PCSK9 inhibition in Subjects with Genetic LDL disorders (TAUSSIG)

About the speaker

Professor Frederick Raal

8 more presentations in this session

Risk of incident atherosclerotic cardiovascular disease events by atherogenic lipid levels in a real-world population of 62,428 on-statin individuals with diabetes

Assessing gaps in cholesterol treatment guidelines for primary prevention of cardiovascular disease using clinical trial evidence: results from the prospective population-based Rotterdam Study

Effects of morning versus evening statin therapy on lipid profile: A systematic review and meta-analysis

Familial hypercholesterolemia: development of a next generation sequencing approach to the disease

Comprehensive genotyping and phenotyping in patients with severe hypercholesterolemia

Access the full session

Lipid lowering therapy in primary cardiovascular prevention

About the event

ESC Congress 2017

ESC 365 is supported by